Summary
Boston Scientific Corporation (BSX) reported strong financial results for the third quarter and first nine months of 2023. Net sales increased by 11.2% to $3.527 billion in Q3 2023 and by 11.4% to $10.515 billion for the nine-month period, driven by robust operational growth across its diverse product portfolio and strategic acquisitions. The company demonstrated significant profitability, with net income attributable to common stockholders rising to $505 million ($0.34 per diluted share) in Q3 2023 and $1.065 billion ($0.73 per diluted share) for the nine-month period. Key operational improvements and strategic acquisitions, including Apollo Endosurgery and Acotec Scientific Holdings, contributed positively to revenue growth. The company also managed its expenses effectively, with R&D expenses increasing to support innovation and SG&A expenses growing proportionally with sales. While facing some supply chain pressures and inflationary impacts, Boston Scientific maintained a healthy gross profit margin and continued to invest in its pipeline. The company also resolved significant patent litigation, resulting in a substantial credit. Overall, BSX presented a solid financial performance with strong top-line growth and profitability.
Financial Highlights
50 data points| Revenue | $3.53B |
| Cost of Revenue | $1.10B |
| Gross Profit | $2.43B |
| SG&A Expenses | $1.24B |
| Operating Expenses | $1.73B |
| Operating Income | $693.00M |
| Interest Expense | $66.00M |
| Net Income | $504.00M |
| EPS (Basic) | $0.34 |
| EPS (Diluted) | $0.34 |
| Shares Outstanding (Basic) | 1.46B |
| Shares Outstanding (Diluted) | 1.48B |
Key Highlights
- 1Net sales for Q3 2023 grew 11.2% to $3.527 billion, and 11.4% for the nine months to $10.515 billion, indicating strong market demand and effective sales execution.
- 2Net income attributable to common stockholders was $505 million ($0.34 per diluted share) for Q3 and $1.065 billion ($0.73 per diluted share) for the first nine months, demonstrating significant profitability.
- 3Operational net sales growth was 11.1% in Q3 and 11.9% organically for the nine months, reflecting broad-based growth across segments and acquisitions.
- 4Acquisitions, including Apollo Endosurgery and a majority stake in Acotec, are contributing to revenue growth and strategic positioning.
- 5The company resolved significant patent litigation with Cook Group, resulting in a $158 million award and a subsequent settlement.
- 6Gross profit margin remained strong at 68.8% for Q3 and improved to 69.6% for the nine months, despite some currency headwinds.
- 7Boston Scientific continues to invest in R&D, with expenses increasing by 5% in Q3 and 6% for the nine months, supporting its innovation pipeline.